Author Archives: Alexis BERNARD

AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share

18/12/2025 – AB Science SA announces the initiation of coverage of its stock by Maxim Group, an independent US-based full-service investment bank, securities and wealth management firm

AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers

15/12/2025 – AB Science today announced the publication of a new AB8939 article on the preprint platform bioRxiv

AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function

11/12/2025 – AB Science today announced the publication of a new article on MedRxiv, presenting a post-hoc subgroup analysis of the phase 2b/3 AB10015 study

AB Science announces the successful completion of a 2.8 million euros private placement

17/10/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 2.8 million subscribed by a limited number of investors

Summary of the virtual conference held on October 16, 2025

16/10/2025 – AB Science provides intitial Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia

AB Science webcast of October 16, 2025

16/10/2025 – Presentation of the AB Science webcast held on October 16, 2025

AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm to 3pm CET to provide an update on the Phase 1 study with AB8939

14/10/2025 – The purpose of this virtual conference will be to present in more detail the initial clinical data on the combination of AB8939 + venetoclax in the first three patients with refractory and relapsed AML

Revenues for the first half of 2025 and update on AB Science’s activities

10/10/2025 – AB Science today reports its revenues for the first half of 2025 and provides an update on its activities

AB Science announces a slight delay in the publication of its 2025 half-year financial report

30/09/2025 – The Company will publish its financial report for the first half of 2025 on Friday 10 October, 2025, at the latest

AB Science announces the successful completion of a 2.55 million euros private placement

04/08/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 2.55 million subscribed by a limited number of investors